Several studies have identified genetic variants, such as single nucleotide polymorphisms (SNPs), that increase individual susceptibility to the cardiotoxic effects of cancer therapies, particularly anthracyclines and HER2 inhibitors. The gene discussed is ERBB2; the disease is cancer.